1. Arbutus Biopharma Appoints New CEO and Restructures Board to Prioritize LNP Technology
Release Date: February 25, 2025
Source: GlobeNewswire
Authors: Lindsay Androski (CEO), Roivant Sciences Team
Arbutus Biopharma announced a leadership overhaul, appointing Lindsay Androski, J.D., M.B.A., as CEO, effective immediately. Androski, a biotechnology veteran with expertise in lipid nanoparticle (LNP) intellectual property litigation, replaces interim CEO Michael McElhaugh. The board was restructured to include four new directors, signaling a strategic focus on advancing LNP delivery technology for infectious diseases like hepatitis B and leveraging partnerships through Genevant Sciences.
The company paused investor engagements to reassess development plans for its hepatitis B candidate, imdusiran AB-729, and explore LNP-driven collaborations. Arbutus’s LNP platform, licensed via Genevant, remains central to its mission, with analysts highlighting potential upside due to its $640 million market cap and strong liquidity position.
2. YOLT-203 Gene-Editing Therapy Shows Efficacy in Phase 1 Trial for Rare Kidney Disease
Release Date: February 25, 2025
Source: Urology Times
Link: YOLT-203 Phase 1 Results
Authors: Yuxuan Wu (CEO, YolTech Therapeutics), et al.
YolTech Therapeutics reported positive Phase 1 data for YOLT-203, an LNP-delivered gene-editing therapy targeting primary hyperoxaluria type 1 (PH1). In the trial (NCT06511349), seven PH1 patients received intravenous doses of 0.3–0.6 mg/kg. The highest dose cohort achieved a 70% reduction in urinary oxalate levels sustained over 16 weeks, with no serious adverse events.
YOLT-203 uses the proprietary YolCas12HF system to edit the AGXT gene, correcting oxalate metabolism defects. The therapy, granted Orphan Drug and Rare Pediatric Disease designations in 2024, represents a potential one-time cure for PH1. Preclinical studies confirmed LNPs effectively deliver mRNA to liver cells, enabling precise in vivo editing.
3. Mount Sinai’s Blood-Brain Barrier-Crossing LNPs Enable mRNA Delivery to the Brain
Release Date: February 25, 2025
Source: ScienceDailyLink: Brain-Targeted LNPs
Authors: Yizhou Dong, PhD (Icahn School of Medicine at Mount Sinai), et al.
Researchers at Mount Sinai developed blood-brain barrier-crossing lipid nanoparticles (BLNPs) capable of delivering mRNA to the brain via intravenous injection. Published in Nature Materials, the study demonstrated that BLNPs achieved 30% transfection efficiency in neurons and astrocytes across mouse models and human brain tissue.
The optimized MK16 BLNP formulation outperformed FDA-approved LNPs, leveraging natural transport mechanisms to cross the blood-brain barrier. Applications include treating Alzheimer’s, ALS, and brain tumors by instructing cells to produce therapeutic proteins. Preclinical trials showed reduced amyloid-beta plaques in Alzheimer’s models and inhibited glioblastoma growth.
Summary of Key Developments:
Arbutus Leadership: Strategic pivot to LNP-driven partnerships under new CEO Lindsay Androski.
YOLT-203: Breakthrough gene-editing LNPs for rare kidney disease.
Mount Sinai BLNPs: Revolutionary brain-targeted mRNA delivery system.
These advancements underscore LNPs' expanding role in gene therapy, neurology, and biopharma strategy, with transformative clinical applications on the horizon.
Comments